Davide Capodanno/X
Nov 4, 2025, 09:10
OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
Davide Capodanno, Professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, posted on X.
“In this post hoc analysis of patients with acute coronary syndromes in the OCCUPI trial, the primary outcome—1-year composite of cardiac death, myocardial infarction, stent thrombosis, or ischemia-driven target vessel revascularisation—occurred in 4.9% of the OCT-guided group versus 9.5% in the angiography-guided group (HR 0.50, 95% CI 0.29–0.87; p=0.011; p=0.273 for interaction). Such benefit was particularly observed in patients who achieved stent optimisation by OCT.”
Read ARTICLE here EDITORIAL here.
Stay updated with Hemostasis Today.
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge